Abstract
Germ-line mutations in the TP53 gene are rare, but predispose women to a range of cancer types, including early-onset breast cancer. Breast cancers in women from families with the Li-Fraumeni syndrome often occur before age 30. The prevalence of deleterious TP53 mutations in unselected women with early-onset breast cancer is not precisely known. If mutations were found to be sufficiently common, it might be prudent to offer genetic testing to affected women in this age group. We screened the entire TP53 gene in the germ-line DNA from 95 women of various ethnic groups who were diagnosed with breast cancer before age 30, and who had previously been found to be negative for BRCA1 and BRCA2 mutations. No TP53 mutation was found. This study does not support a policy that TP53 testing should be offered routinely to unselected women with early-onset breast cancer in the absence of a family history of cancer.
Similar content being viewed by others
References
Narod SA, Foulkes WD (2004) BRCA1 and BRCA2; 1994 and beyond. Nat Rev Cancer 4:665–676
Li FP, Fraumeni JF Jr (1969) Soft tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 71:747–752
Li FP, Fraumeni JF Jr, Mulvihill JJ et al (1988) A cancer family syndrome in twenty-four kindreds. Cancer Res 48:5358–5362
Garber JE, Goldstein AM, Kantor AF et al (1991) Follow up study of twenty-four families with Li-Fraumeni syndrome. Cancer Res 51:6069–6097
Malkin D, Li FP, Strong LC et al (1990) Germline p53 mutations in a familial syndrome of breast cancer, sarcoma, and other neoplasms. Science 250:1233–1238
Birch JM, Hartley AL, Tricker KJ et al (1994) Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 54:1298–1304
Salmon A, Amikam D, Sodha N, Davidson S, Basel-Vanagaite L, Eeles RA, Abeliovich D, Peretz T (2007) Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline ‘de-novo’ TP53 mutation. Clin Oncol (R Coll Radiol) 19(7):490–493
De Leon Matsuda ML, Liede A, Kwan E, Mapua CA, Cutiongco EM, Tan A, Borg A, Narod SA (2002) BRCA1 and BRCA2 mutations among breast cancer patients from the Philippines. Int J Cancer 98(4):596–603
Liede A, Malik IA, Aziz Z, Rios Pd Pde L, Kwan E, Narod SA (2002) Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan. Am J Hum Genet 71(3):595–606
Gomes MC, Costa MM, Borojevic R, Monteiro AN, Vieira R, Koifman S, Koifman RJ, Li S, Royer R, Zhang S, Narod SA (2007) Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil. Breast Cancer Res Treat 103(3):349–353
Rozen S, Skaletsky HJ (2000) Primer3 on the WWW for general users and for biologist programmers. In: Krawetz S, Misener S (eds) Bioinformatics methods and protocols: methods in molecular biology. Humana Press, New Jersey, pp 365–386
Reese MG, Eeckman FH, Kulp D, Haussler D (1997) Improved splice site detection in Genie. J Comput Biol 4(3):311–323
Smith PJ, Zhang C, Wang J, Chew SL, Zhang MQ, Krainer AR (2006) An increased specificity score matrix for the prediction of SF2/ASF-specific exonic splicing enhancers. Hum Mol Genet 15(16):2490–2508
Manoukian S, Peissel B, Pensotti V et al (2007) Germline mutations of TP53 and BRCA2 genes in breast cancer/sarcoma families. Eur J Cancer 43(3):601–606
Krasteva ME, Georgieva EI (2006) Germline p53 single-base changes associated with Balkan endemic nephropathy. Biochem Biophys Res Commun 342(2):562–567
Keller G, Vogelsang H, Becker I et al (2004) Germline mutations of the E-cadherin (CDH1) and TP53 genes, rather than of RUNX3 and HPP1, contribute to genetic predisposition in German gastric cancer patients. J Med Genet 41(6):e89
Dearth LR, Qian H, Wang T et al (2007) Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers. Carcinogenesis 28(2):289–298
Shiraishi K, Kato S, Han SY et al (2004) Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library. J Biol Chem 279(1):348–355
Resnick MA, Inga A (2003) Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity. Proc Natl Acad Sci USA 100(17):9934–9939
Monti P, Campomenosi P, Ciribilli Y et al (2003) Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay. Oncogene 22(34):5252–5260
Maurici D, Monti P, Campomenosi P et al (2001) Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay. Oncogene 20(27):3533–3540
Smith PD, Crossland S, Parker G et al (1999) Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions. Oncogene 18(15):2451–2459
Flaman JM, Robert V, Lenglet S et al (1998) Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast. Oncogene 16(10):1369–1372
Tinat J, Bougeard G, Baert-Desurmont et al (2009) 2009 version of the Chompret criteria for Li-Fraumeni syndrome. J Clin Oncol (Epub August)
Borresen A-L, Andersen TI, Garber J et al (1992) Screening for germ line TP53 mutations in breast cancer patients. Cancer Res 52:3234–3236
Eeles RA (1995) Germline mutations in the TP53 gene. Cancer Surv 25:10–24
Laloo F, Varley J, Moran A et al (2006) BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur J Cancer 42:1143–1150
Gonzalez KD, Noltner KA, Buzin CH, Gu D, Wen-Fung CY, Nguyen Q, Han JH et al (2009) Beyond Li-Fraumeni syndrome, clinical characteristics of families with p53 germline mutations. J Clin Oncol 27:1250–1256
Bougeard G, Sesboue R, Baert-Desurmont S et al (2008) Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J Med Genet 45(8):535–538
Evans DG, Wu CL, Birch JM (2008) BRCA2: a cause of the Li-Fraumeni like syndrome. J Med Genet 45:62–63
Walsh T, Casadei S, Coats KH et al (2006) Spectrum of mutations in BRCA1, BRCA2, CHEK2 and TP53 in families at high risk of breast cancer. JAMA 295(12):1379–1388
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ginsburg, O.M., Akbari, M.R., Aziz, Z. et al. The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30. Familial Cancer 8, 563–567 (2009). https://doi.org/10.1007/s10689-009-9287-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10689-009-9287-z